Literature DB >> 1653072

Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater.

M G Buzzi1, M A Moskowitz, S J Peroutka, B Byun.   

Abstract

1. We describe the effects of pretreatment with 5-hydroxytryptamine (5-HT) receptor agonists and antagonists on neurogenically-mediated plasma protein extravasation ([125I]-albumin) in rat dura mater and in extracranial tissues (temporalis muscle fascia, conjunctiva, eyelid and lip) induced by electrical stimulation of the right trigeminal ganglion. 2. Leakage of [125I]-bovine serum albumin from blood vessels in dura mater following high intensity stimulation (1.2 mA, 5 ms, 5 Hz for 5 min) was significantly reduced by the intravenous administration of drugs active at 5-HT receptors with some selectivity for the 5-HT1 receptor subtypes: 5-carboxamidotryptamine (5-CT) (threshold dose, 1 ng kg-1); 5-benzyloxytryptamine (5-BT) (10, 30 or 100 micrograms kg-1); 8-hydroxydipropylaminotetralin (8-OH-DPAT) (300 micrograms kg-1); and as previously reported, sumatriptan (100 micrograms kg-1), dihydroergotamine (DHE) (50 micrograms kg-1); ergotamine tartrate (100 micrograms kg-1) and chronically administered methysergide (1 mg kg-1). 3. The putative 5-HT receptor antagonist, metergoline 100 micrograms kg-1, inhibited partially the effect of sumatriptan in dura mater providing additional evidence for a 5-HT1 receptor subtype-mediated mechanism, although it was not effective against 5-CT (1 ng kg-1). Methiothepin (300 micrograms kg-1) did not affect the response to sumatriptan. When administered at high concentrations (1 mg kg-1) methiothepin and metergoline decreased plasma protein extravasation in rat dura mater. 4. Pretreatment with the 5-HT2 receptor antagonists pizotifen, 300pugkg 1, or ketanserin, 300,ugkg ', or the 5-HT3 receptor antagonists MDL 72222, 300,ugkg-1, or ICS 205-930, 300pgkg-1, did not affect plasma protein leakage following electrical trigeminal stimulation. Blockade by sumatriptan of plasma protein extravasation was not inhibited by pizotifen (300,ug kg-1) or MDL 72222 (300pg kg- '). 5. The 5-HT receptor(s) mediating this response were present only on intracranial tissues innervated by the trigeminal nerve; plasma protein extravasation in extracranial tissues was not blocked by pretreatment with the equivalent or higher concentrations of the above drugs following low intensity trigeminal stimulation (0.1 mA, 5 ms, 5 Hz). 6. The putative 5-HT receptor(s) mediating this response were not present on sympathetic fibres innervating dura mater since unilateral removal of the superior cervical ganglion did not prevent the development of plasma protein extravasation nor did it affect the blockade by sumatriptan IOOpug kg- '. 7. The above pharmacological data suggest that intracranial vessels possess 5-HT receptor(s) which are coupled to inhibition of neurogenically-mediated plasma protein extravasation. These receptors cannot be detected on extracranial cephalic blood vessels innervated by the trigeminal nerve, although available evidence strongly suggests that the 5-HT receptors reside on perivascular trigeminal nerve fibres. The rank order of effective doses (threshold concentrations; 5-CT < 5-BT < DHE < sumatriptan < 8-OHDPAT) is most consistent with a 5-HTlB- or 5-HTlD-mediated response, among the known 5-HT1 family of receptors. However, the lack of effect of methiothepin against the actions of sumatriptan, or metergoline against the effects of 5-CT suggest important differences and the possibility that a previously unrecognized 5-HT receptor(s) is involved in this response.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1653072      PMCID: PMC1908367          DOI: 10.1111/j.1476-5381.1991.tb09805.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

1.  Neurohumoral features of afferent fibers in man. Their role in vasodilation, inflammation, and pain.

Authors:  L F CHAPMAN; A O RAMOS; H GOODELL; H G WOLFF
Journal:  Arch Neurol       Date:  1961-06

2.  Characterization of the 5-HT1B recognition site in rat brain: binding studies with (-)[125I]iodocyanopindolol.

Authors:  D Hoyer; G Engel; H O Kalkman
Journal:  Eur J Pharmacol       Date:  1985-11-26       Impact factor: 4.432

3.  Multiple calcium channels mediate neurotransmitter release from peripheral neurons.

Authors:  T M Perney; L D Hirning; S E Leeman; R J Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

4.  Application of [125I]iodocyanopindolol to measure 5-hydroxytryptamine1B receptors in the brain of the rat.

Authors:  S J Offord; G A Ordway; A Frazer
Journal:  J Pharmacol Exp Ther       Date:  1988-01       Impact factor: 4.030

5.  Selective vasoconstriction in carotid vascular bed by methysergide: possible relevance to its antimigraine effect.

Authors:  P R Saxena
Journal:  Eur J Pharmacol       Date:  1974-06       Impact factor: 4.432

6.  Characterization of a novel 3H-5-hydroxytryptamine binding site subtype in bovine brain membranes.

Authors:  R E Heuring; S J Peroutka
Journal:  J Neurosci       Date:  1987-03       Impact factor: 6.167

7.  GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein.

Authors:  P P Humphrey; W Feniuk; M J Perren; H E Connor; A W Oxford; L H Coates; D Butina
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

8.  Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system.

Authors:  P J Goadsby; L Edvinsson; R Ekman
Journal:  Ann Neurol       Date:  1988-02       Impact factor: 10.422

9.  Molecular pharmacology of 5-HT1D recognition sites: radioligand binding studies in human, pig and calf brain membranes.

Authors:  C Waeber; P Schoeffter; J M Palacios; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-06       Impact factor: 3.000

10.  Species variations in RU 24969 interactions with non-5-HT1A binding sites.

Authors:  R E Heuring; J R Schlegel; S J Peroutka
Journal:  Eur J Pharmacol       Date:  1986-03-18       Impact factor: 4.432

View more
  16 in total

Review 1.  Serotonergic agents in the management of cluster headache.

Authors:  Giorgio Lambru; Manjit Matharu
Journal:  Curr Pain Headache Rep       Date:  2011-04

2.  Strategies for therapeutic hypometabothermia.

Authors:  Shimin Liu; Jiang-Fan Chen
Journal:  J Exp Stroke Transl Med       Date:  2012-01-01

3.  Neuropeptide Y Y2 receptor-mediated attenuation of neurogenic plasma extravasation acting through pertussis toxin-sensitive mechanisms.

Authors:  X J Yu; M A Moskowitz
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

4.  L-694,247: a potent 5-HT1D receptor agonist.

Authors:  M S Beer; J A Stanton; Y Bevan; A Heald; A J Reeve; L J Street; V G Matassa; R J Hargreaves; D N Middlemiss
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

Review 5.  A practical guide to the management and prevention of migraine.

Authors:  H C Diener; H Kaube; V Limmroth
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

6.  Atrial natriuretic peptide (ANP) attenuates brain oedema accompanying experimental subarachnoid haemorrhage.

Authors:  T P Dóczi; F Joó; I Balás
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

7.  Selective 5-HT1D alpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development.

Authors:  G W Rebeck; K I Maynard; B T Hyman; M A Moskowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

8.  The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation.

Authors:  P Gupta; D Brown; P Butler; P Ellis; K L Grayson; G C Land; J E Macor; S F Robson; M J Wythes; N B Shepperson
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

9.  CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges.

Authors:  K Nozaki; M A Moskowitz; P Boccalini
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

10.  Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva.

Authors:  W S Lee; S M Moussaoui; M A Moskowitz
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.